Navigation Links
Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
Date:4/15/2013

SAN DIEGO, April 15, 2013 /PRNewswire/ -- Ambit Biosciences Corporation today announced that David R. Parkinson , M.D., has been appointed to the company's board of directors. Dr. Parkinson is a venture partner at New Enterprise Associates, a position he has held since 2012, and a member of the board of directors for Threshold Pharmaceuticals, a publicly-traded oncology company, and Zyngenia, Inc. He served as a director of Facet Biotech through its acquisition by Abbott in 2010. 

Prior to joining New Enterprise Associates, Dr. Parkinson was president and chief executive officer of Nodality, a biotechnology company focused on personalized medicine. Before this, he held positions as senior vice president of oncology research at Biogen Idec, vice president of oncology development at Amgen, Inc, and vice president of global clinical oncology development at Novartis Corporation. Dr. Parkinson previously held multiple positions with the National Cancer Institute from 1990 to 1997, including chief of the Investigational Drug Branch and associate director of the Cancer Therapy Evaluation Program. He has also served on the National Cancer Policy Forum of the Institute of Medicine and is a past president of the International Society of Biological Therapy. He is a past Chairman of the FDA's Biologics Advisory Committee and member of the FDA Science Board, and is a recipient of the FDA's Cody Medal .  Dr. Parkinson received his medical doctorate from the University of Toronto Faculty of Medicine, with internal medicine and hematology/oncology training at McGill University in Montreal and at New England Medical Center in Boston. He has held academic positions at the M.D. Anderson Cancer Center, University of Texas and New England Medical Center at Tufts University School of Medicine.

"David brings to Ambit extensive medical and industry experience in oncology, which we believe will bring an appropriate perspective for Ambit at this stage," said Michael Martino , President and CEO of Ambit. "We look forward to his contributions toward the development of quizartinib and the rest of our pipeline."

Added Dr. Parkinson, "I look forward to serving as a director and working with the board and management team to help advance the potentially important new therapeutic agents in the Ambit pipeline."

About Ambit Biosciences

Ambit is a privately held biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) and is currently under clinical development in patients with relapsed/refractory acute myeloid leukemia (AML) and in newly diagnosed AML patients in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT). In addition to quizartinib, Ambit's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program.

Contacts:
Ian Stone or David Schull (Media)
Russo Partners
(619) 308-6541
(212) 845-4271
ian.stone@russopartnersllc.com  
david.schull@russopartnersllc.com


'/>"/>
SOURCE Ambit Biosciences Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
2. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
3. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
4. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
5. Cleave Biosciences Adds New Investor and $10 Million to Series A Financing
6. Neurocrine Biosciences Announces the Start of Phase IIb Study of Elagolix in Uterine Fibroids
7. Industry Veteran Katrine Bosley Joins Genocea Biosciences Board Of Directors
8. Pressure BioSciences, Inc. to Present at the SeeThruEquity Spring Investor Microcap Forum
9. Neurocrine Biosciences To Present At The 25th Annual Roth Conference
10. Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
11. Presage Biosciences Announces Strategic Research Alliance with Celgene Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... Oct. 2, 2017  AllianceRx Walgreens Prime, the combined ... Walgreens and pharmacy benefit manager Prime Therapeutics LLC (Prime), ... which included the unveiling of new signage at its ... well as at a few other company-owned facilities across ... to patients, some of whom will begin to see ...
(Date:9/28/2017)... Sept. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: ... conference call and webcast on Friday, November 3, 2017, ... and ending at approximately 8:30 a.m. (CDT) / 9:30 ... company,s 2017 financial performance and guidance for 2018, Hill-Rom ... to enhance operational performance, and long-range financial outlook through ...
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017  DarioHealth ... and big data solutions, today announced that its MyDario product is expected ... local TV listings for when The Dr. Oz Show airs in your ... The nine-time Emmy ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and ... of published author, William Nowers. Captain Nowers and his wife, Millie, have six ... years in the Navy. Following his career as a naval aviator and carrier ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris ... of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking ... in the field of medical informatics, this prestigious award is presented to an individual ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
Breaking Medicine News(10 mins):